JAK2 and myeloproliferative neoplasm: Interestingly, PV patient cells supported the growth of both TET2- and TP53-mutant cells moreso than MF patient cells, a finding consistent with clinical reports that the JAK2-mutant MPN to JAK2 wild-type sAML trajectory is more common in PV patients11,13.